Lv1
30 积分 2025-06-10 加入
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
21天前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
24天前
已完结
Ulcerative colitis: moving beyond the mucosal dogma
2个月前
已完结
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
2个月前
已完结
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
2个月前
已完结
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
3个月前
已完结
Global consensus statement on the management of pregnancy in inflammatory bowel disease
3个月前
已完结
Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
3个月前
已关闭
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
3个月前
已完结
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
7个月前
已完结
皖公网安备34019202002308
